Mannose Oligosaccharide‐Conjugated In Situ Pore‐Forming Injectable Hydrogels for Rheumatoid Arthritis Treatment by Reprogramming Macrophage Extracellular Vesicles
Small Methods · 2026
DOI: 10.1002/smtd.202500605 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small Methods, 2026. Verfasst von Anan Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Basic Science Center Project of National Natural Science Foundation of China, Frontiers Science Center for Materiobiology and Dynamic Chemistry, Key …. Hauptthemen laut MEDLINE: Extracellular Vesicles, Macrophages, Hydrogels, Mannose. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Ministry of Science and Technology of the People's Republic of China, Frontiers Science Center for Materiobiology and Dynamic Chemistry.
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes severe cartilage erosion in joints. Current treatments are limited in accessing a 3D platform that not only supports chondrocyte recovery and new cartilage matrix formation but also effectively modulates the inflammatory environment, particularly through macrophage regulation and extracellular vesicle (EV)‐mediated functions. Here, an injectable hydrogel is developed incorporating mannose oligosaccharide (MOS)‐modified chondroitin sulfate and hyaluronic. This hydrogel forms a porous structure in situ, supporting cell adhesion and matrix production. The MOS groups grafted onto the hydrogel bind to CD206 receptors of macrophages, selectively recruiting and regulating M2 macrophages over an extended period. These macrophages, in turn, release EVs with potent anti‐inflammatory properties, which support new cartilage formation and preservation. This innovative approach addresses a critical gap in RA treatment, offering a novel, cost‐effective, and efficient tissue‐engineering solution with the potential to significantly improve patient outcomes and quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Basic Science Center Project of National Natural Science Foundation of China, Frontiers Science Center for Materiobiology and Dynamic Chemistry, Key Laboratory for Ultrafine Materials of Ministry of Education and School…
- Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, 77030, USA.
- Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Förderung
- National Natural Science Foundation of China
- Ministry of Science and Technology of the People's Republic of China
- Frontiers Science Center for Materiobiology and Dynamic Chemistry
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Zhang, A., Ma, Y., Liu, Y., Dong, S., Torres, M. N., Kim, B. Y. S., Liu, C., Sun, L., Yuan, Y., & Jiang, W. (2026). Mannose Oligosaccharide‐Conjugated In Situ Pore‐Forming Injectable Hydrogels for Rheumatoid Arthritis Treatment by Reprogramming Macrophage Extracellular Vesicles. Small Methods. https://doi.org/10.1002/smtd.202500605
Vancouver
Zhang A, Ma Y, Liu Y, Dong S, Torres MN, Kim BYS, et al. Mannose Oligosaccharide‐Conjugated In Situ Pore‐Forming Injectable Hydrogels for Rheumatoid Arthritis Treatment by Reprogramming Macrophage Extracellular Vesicles. Small Methods. 2026. doi:10.1002/smtd.202500605
BibTeX
@article{Zhang2026,
author = {Zhang, Anan and Ma, Yifan and Liu, Yutong and Dong, Shiyan and Torres, Michelle Najarro and Kim, Betty Y S and Liu, Changsheng and Sun, Lili and Yuan, Yuan and Jiang, Wen},
title = {Mannose Oligosaccharide‐Conjugated In Situ Pore‐Forming Injectable Hydrogels for Rheumatoid Arthritis Treatment by Reprogramming Macrophage Extracellular Vesicles},
journal = {Small Methods},
year = {2026},
doi = {10.1002/smtd.202500605}
}
EUVIMED